Transition Metal Based Anticancer Drugs

K.      Benjamin Garbutcheon-Singh; Maxine      P. Grant; Benjamin      W. Harper; Anwen      M. Krause-Heuer; Madhura      Manohar; Nikita      Orkey; Janice      R. Aldrich-Wright

doi:10.2174/156802611794785226

Abstract

With an ageing baby-boomer population in the Western World, cancer is becoming a significant cause of death. The prevalence of cancer and all associated costs, both in human and financial terms, drives the search for new therapeutic drugs and treatments. Platinum anticancer agents, such as cisplatin have been highly successful but there are several disadvantages associated with their use. What is needed are new compounds with different mechanisms of action and resistance profiles. What needs to be recognised is that there are many other metals in the periodic table with therapeutic potential. Here we have highlighted metal complexes with activity and illustrate the different approaches to the design of anticancer complexes.

Keywords: Platinum, ruthenium, copper, palladium, titanium, vanadium, cobalt, gold, Cancer, platinum complexes, drug design, Electrostatic binding, Carboplatin, maximum